Prior research on the potential role of cytokines found that IL-6 signaling can reprogram and alter T-cell immune responses ...

A pairing of two experimental drugs inhibits tumor growth and blocks drug-induced resistance in ovarian cancer, according to a preclinical study led by Weill Cornell Medicine investigators. The ...

Ovarian cancer management is challenging due to high morbidity and mortality, often from late-stage diagnoses. Advances in tumor genomics have led to targeted therapies, improving outcomes for ...

Scientists from King's College London have successfully applied a new technology that disarms one of the most potent weapons ...

One of the biggest challenges in cancer treatment is chemoresistance: Tumors that initially respond well to chemotherapy ...

Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...

Stenoparib, targeting PARP1/2 and tankyrase 1/2, offers a unique mechanism for treating advanced ovarian cancer. The FDA's fast track designation facilitates expedited development and review, with ...